These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 25826229)

  • 21. [Monoclonal antibodies and cancer].
    López González JS; Selman Lama M
    Salud Publica Mex; 1985; 27(3):213-34. PubMed ID: 2996157
    [No Abstract]   [Full Text] [Related]  

  • 22. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.
    Qi Y; Chen L; Liu Q; Kong X; Fang Y; Wang J
    Front Immunol; 2020; 11():563258. PubMed ID: 33488573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
    Phan GQ; Yang JC; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Restifo NP; Haworth LR; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; Duray PH; Steinberg SM; Allison JP; Davis TA; Rosenberg SA
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8372-7. PubMed ID: 12826605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging Opportunities and Challenges in Cancer Immunotherapy.
    Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
    Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complement in cancer and cancer immunotherapy.
    Kolev M; Towner L; Donev R
    Arch Immunol Ther Exp (Warsz); 2011 Dec; 59(6):407-19. PubMed ID: 21960413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The expanding role of immunotherapy.
    Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J
    Cancer Treat Rev; 2017 Mar; 54():74-86. PubMed ID: 28231560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer immunotherapy.
    Baxevanis CN; Perez SA; Papamichail M
    Crit Rev Clin Lab Sci; 2009; 46(4):167-89. PubMed ID: 19650714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetically engineered antibodies for direct antineoplastic treatment and systematic delivery of various therapeutic agents to cancer cells.
    Bodey B
    Expert Opin Biol Ther; 2001 Jul; 1(4):603-17. PubMed ID: 11727497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Target cell induced T cell activation with bispecific antibodies: a new concept for tumor immunotherapy.
    Wolf H; Freimann U; Jung G
    Recent Results Cancer Res; 1994; 135():185-95. PubMed ID: 8047693
    [No Abstract]   [Full Text] [Related]  

  • 31. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The translational potential for target validation and therapy using intracellular antibodies in oncology.
    Weidle UH; Maisel D; Brinkmann U; Tiefenthaler G
    Cancer Genomics Proteomics; 2013; 10(6):239-50. PubMed ID: 24336633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy of cancer: from vision to standard clinical practice.
    Huber CH; Wölfel T
    J Cancer Res Clin Oncol; 2004 Jul; 130(7):367-74. PubMed ID: 15067541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Approaches for Immune Directed Treatment for Ovarian Cancer.
    Hardwick N; Frankel PH; Cristea M
    Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor Antibodies Can Drive Therapeutic T Cell Responses.
    Wittrup KD
    Trends Cancer; 2017 Sep; 3(9):615-620. PubMed ID: 28867165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antibodies for the immunotherapy of solid tumours.
    Mauerer R; Gruber R
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1385-98. PubMed ID: 22339220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccines in the treatment of cancer.
    Baltz JK
    Am J Health Syst Pharm; 1995 Nov; 52(22):2574-85; quiz 2594-5. PubMed ID: 8590245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
    Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
    J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel immune-based treatment strategies for chronic lymphocytic leukemia.
    Wierda WG; Kipps TJ; Keating MJ
    J Clin Oncol; 2005 Sep; 23(26):6325-32. PubMed ID: 16155015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapeutic approaches for cancer therapy: An updated review.
    Kazemi T; Younesi V; Jadidi-Niaragh F; Yousefi M
    Artif Cells Nanomed Biotechnol; 2016 May; 44(3):769-79. PubMed ID: 25801036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.